Chishala Chabala
Overview
Explore the profile of Chishala Chabala including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
413
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Bevers L, Waalewijn H, Szubert A, Chabala C, Bwakura-Dangarembizi M, Makumbi S, et al.
Clin Infect Dis
. 2023 Jun;
77(9):1312-1317.
PMID: 37280040
Background: Dolutegravir (DTG), combined with a backbone of 2 nucleoside reverse transcriptase inhibitors, is currently the preferred first-line treatment for human immunodeficiency virus (HIV) in childhood. CHAPAS4 is an ongoing...
12.
Jacobs T, Mumbiro V, Chitsamatanga M, Namuziya N, Passanduca A, Dominguez-Rodriguez S, et al.
J Acquir Immune Defic Syndr
. 2023 Feb;
93(1):42-46.
PMID: 36724434
Background: Although super-boosted lopinavir/ritonavir (LPV/r; ratio 4:4 instead of 4:1) is recommended for infants living with HIV and receiving concomitant rifampicin, in clinical practice, many different LPV/r dosing strategies are...
13.
Marcy O, Wobudeya E, Font H, Vessiere A, Chabala C, Khosa C, et al.
Lancet Infect Dis
. 2022 Nov;
23(3):341-351.
PMID: 36395782
Background: Tuberculosis diagnosis might be delayed or missed in children with severe pneumonia because this diagnosis is usually only considered in cases of prolonged symptoms or antibiotic failure. Systematic tuberculosis...
14.
Gafar F, Wasmann R, McIlleron H, Aarnoutse R, Schaaf H, Marais B, et al.
Eur Respir J
. 2022 Nov;
61(3).
PMID: 36328357
Background: Suboptimal exposure to antituberculosis (anti-TB) drugs has been associated with unfavourable treatment outcomes. We aimed to investigate estimates and determinants of first-line anti-TB drug pharmacokinetics in children and adolescents...
15.
Rojo P, Moraleda C, Tagarro A, Dominguez-Rodriguez S, Castillo L, Prieto Tato L, et al.
Trials
. 2022 Jun;
23(1):531.
PMID: 35761406
Background: Pneumonia is the primary cause of death among HIV-infected children in Africa, with mortality rates as high as 35-40% in infants hospitalized with severe pneumonia. Bacterial pathogens and Pneumocystis...
16.
Tikiso T, McIlleron H, Abdelwahab M, Bekker A, Hesseling A, Chabala C, et al.
J Antimicrob Chemother
. 2022 Apr;
77(7):1949-1959.
PMID: 35466379
Objectives: Ethambutol protects against the development of resistance to co-administered drugs in the intensive phase of first-line anti-TB treatment in children. It is especially relevant in settings with a high...
17.
Turkova A, Wills G, Wobudeya E, Chabala C, Palmer M, Kinikar A, et al.
N Engl J Med
. 2022 Mar;
386(10):911-922.
PMID: 35263517
Background: Two thirds of children with tuberculosis have nonsevere disease, which may be treatable with a shorter regimen than the current 6-month regimen. Methods: We conducted an open-label, treatment-shortening, noninferiority...
18.
du Preez K, Gabardo B, Kabra S, Triasih R, Lestari T, Kal M, et al.
Pathogens
. 2022 Feb;
11(2).
PMID: 35215139
Over the past 15 years, and despite many difficulties, significant progress has been made to advance child and adolescent tuberculosis (TB) care. Despite increasing availability of safe and effective treatment...
19.
Vonasek B, Radtke K, Vaz P, Buck W, Chabala C, McCollum E, et al.
Expert Rev Respir Med
. 2022 Feb;
16(3):273-284.
PMID: 35175880
Introduction: With growing attention globally to the childhood tuberculosis epidemic after decades of neglect, and with the burden of severe acute malnutrition (SAM) remaining unacceptably high worldwide, the collision of...
20.
Chabala C, Turkova A, Hesseling A, Zimba K, Van Der Zalm M, Kapasa M, et al.
Clin Infect Dis
. 2021 Aug;
74(10):1767-1775.
PMID: 34420049
Background: Dispersible pediatric fixed-dose combination (FDC) tablets delivering higher doses of first-line antituberculosis drugs in World Health Organization-recommended weight bands were introduced in 2015. We report the first pharmacokinetic data...